Abstract
Membrane proteins comprise nearly half of the drug targets and are the preferred targets for majority of the FDA approved small-molecule drugs. GPCRs, ion channels, and kinases are leading drug targets because of their druggability, and because of availability of high-resolution three-dimensional structures. Solute carriers (SLC) and major facilitator superfamily (MFS) members are linked to more than 100 human diseases and have been pursued as lucrative drug targets. Functional mapping and attempts at structural characterization of SLCs and MFSs belonging to unique transporter classes have enabled structure-based drug design and pharmacological targeting of those families.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
